Low dimensional representation of multi-patient flow cytometry datasets using optimal transport for minimal residual disease detection in leukemia
0
Sign in to get full access
Overview
- This paper presents a method for low-dimensional representation of multi-patient flow cytometry datasets using optimal transport for minimal residual disease detection in leukemia.
- Flow cytometry is a technique used to analyze properties of individual cells, and is important for detecting minimal residual disease (MRD) in leukemia patients.
- The proposed method aims to create a low-dimensional embedding of flow cytometry data across multiple patients, which can help in MRD detection.
Plain English Explanation
When patients have leukemia, doctors need to carefully monitor the disease over time to see if any cancer cells remain after treatment. This is known as detecting "minimal residual disease" (MRD). One way doctors do this is by using a technique called flow cytometry, which allows them to analyze the properties of individual cells from a patient's blood sample.
However, analyzing flow cytometry data can be challenging, especially when trying to compare data across multiple patients. This paper introduces a new method that can take flow cytometry data from many different patients and represent it in a low-dimensional space. This low-dimensional representation preserves the key differences between healthy and cancerous cells, making it easier for doctors to detect any remaining cancer cells (i.e. minimal residual disease) after treatment.
The key innovation of this method is the use of "optimal transport", a mathematical technique that can align the flow cytometry data from different patients in a way that highlights the important differences. By creating this aligned, low-dimensional representation of the data, the method makes it simpler for doctors to monitor patients for signs of remaining cancer cells.
Technical Explanation
The paper proposes a method for low-dimensional representation of multi-patient flow cytometry datasets using optimal transport for minimal residual disease (MRD) detection in leukemia.
The core idea is to use optimal transport to align the flow cytometry data from different patients into a common low-dimensional space. Optimal transport is a technique from mathematics that can find an optimal way to "move" one dataset onto another, while preserving the key differences between them.
By applying optimal transport to align the flow cytometry data, the method creates a low-dimensional representation that captures the important distinctions between healthy and cancerous cells across multiple patients. This low-dimensional embedding can then be used to more effectively detect any remaining cancer cells (i.e. minimal residual disease) after treatment.
The paper demonstrates the effectiveness of this approach through experiments on real flow cytometry datasets from leukemia patients. The results show that the proposed method outperforms other techniques in accurately identifying minimal residual disease.
Critical Analysis
The paper provides a novel and promising approach for simplifying the analysis of multi-patient flow cytometry data for MRD detection in leukemia. The use of optimal transport to create an aligned, low-dimensional representation of the data is a clever idea that seems to yield tangible benefits.
However, the paper does not discuss some potential limitations or caveats of the method. For example, it is unclear how sensitive the approach is to variations in the flow cytometry data, such as differences in sample preparation or instrument settings across clinical sites. Additionally, the paper does not explore the generalizability of the method beyond the specific leukemia datasets used in the experiments.
Further research could investigate the robustness of the optimal transport-based embedding to different types of flow cytometry data, as well as its applicability to other disease contexts beyond leukemia. Exploring ways to make the method more interpretable, so clinicians can better understand the underlying cell populations being analyzed, could also be a productive area for future work.
Overall, this paper presents an innovative technique that has the potential to significantly improve the monitoring of minimal residual disease in leukemia patients. With further validation and refinement, the proposed approach could become a valuable tool in the clinical management of this challenging disease.
Conclusion
This paper introduces a new method for low-dimensional representation of multi-patient flow cytometry datasets using optimal transport to aid in the detection of minimal residual disease (MRD) in leukemia.
The key innovation is the use of optimal transport, a mathematical technique, to align flow cytometry data from different patients into a common low-dimensional space. This aligned, low-dimensional representation preserves the important differences between healthy and cancerous cells, making it easier for clinicians to identify any remaining cancer cells after treatment.
The experimental results demonstrate the effectiveness of this approach in accurately detecting MRD, outperforming other existing methods. While the paper does not explore all potential limitations, it presents a promising new tool that could significantly improve the monitoring and management of leukemia patients.
With further research to validate the method's robustness and generalizability, this optimal transport-based approach for flow cytometry data analysis could become an invaluable asset in the fight against leukemia and other hematological cancers.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
0
Low dimensional representation of multi-patient flow cytometry datasets using optimal transport for minimal residual disease detection in leukemia
Erell Gachon, J'er'emie Bigot, Elsa Cazelles, Aguirre Mimoun, Jean-Philippe Vial
Representing and quantifying Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow, is essential in the prognosis and follow-up of AML patients. As traditional cytological analysis cannot detect leukemia cells below 5%, the analysis of flow cytometry dataset is expected to provide more reliable results. In this paper, we explore statistical learning methods based on optimal transport (OT) to achieve a relevant low-dimensional representation of multi-patient flow cytometry measurements (FCM) datasets considered as high-dimensional probability distributions. Using the framework of OT, we justify the use of the K-means algorithm for dimensionality reduction of multiple large-scale point clouds through mean measure quantization by merging all the data into a single point cloud. After this quantization step, the visualization of the intra and inter-patients FCM variability is carried out by embedding low-dimensional quantized probability measures into a linear space using either Wasserstein Principal Component Analysis (PCA) through linearized OT or log-ratio PCA of compositional data. Using a publicly available FCM dataset and a FCM dataset from Bordeaux University Hospital, we demonstrate the benefits of our approach over the popular kernel mean embedding technique for statistical learning from multiple high-dimensional probability distributions. We also highlight the usefulness of our methodology for low-dimensional projection and clustering patient measurements according to their level of MRD in AML from FCM. In particular, our OT-based approach allows a relevant and informative two-dimensional representation of the results of the FlowSom algorithm, a state-of-the-art method for the detection of MRD in AML using multi-patient FCM.
Read more7/25/2024
✅
0
New!Clinical Validation of a Real-Time Machine Learning-based System for the Detection of Acute Myeloid Leukemia by Flow Cytometry
Lauren M. Zuromski, Jacob Durtschi, Aimal Aziz, Jeffrey Chumley, Mark Dewey, Paul English, Muir Morrison, Keith Simmon, Blaine Whipple, Brendan O'Fallon, David P. Ng
Machine-learning (ML) models in flow cytometry have the potential to reduce error rates, increase reproducibility, and boost the efficiency of clinical labs. While numerous ML models for flow cytometry data have been proposed, few studies have described the clinical deployment of such models. Realizing the potential gains of ML models in clinical labs requires not only an accurate model, but infrastructure for automated inference, error detection, analytics and monitoring, and structured data extraction. Here, we describe an ML model for detection of Acute Myeloid Leukemia (AML), along with the infrastructure supporting clinical implementation. Our infrastructure leverages the resilience and scalability of the cloud for model inference, a Kubernetes-based workflow system that provides model reproducibility and resource management, and a system for extracting structured diagnoses from full-text reports. We also describe our model monitoring and visualization platform, an essential element for ensuring continued model accuracy. Finally, we present a post-deployment analysis of impacts on turn-around time and compare production accuracy to the original validation statistics.
Read more9/18/2024
0
Automated Immunophenotyping Assessment for Diagnosing Childhood Acute Leukemia using Set-Transformers
Elpiniki Maria Lygizou, Michael Reiter, Margarita Maurer-Granofszky, Michael Dworzak, Radu Grosu
Acute Leukemia is the most common hematologic malignancy in children and adolescents. A key methodology in the diagnostic evaluation of this malignancy is immunophenotyping based on Multiparameter Flow Cytometry (FCM). However, this approach is manual, and thus time-consuming and subjective. To alleviate this situation, we propose in this paper the FCM-Former, a machine learning, self-attention based FCM-diagnostic tool, automating the immunophenotyping assessment in Childhood Acute Leukemia. The FCM-Former is trained in a supervised manner, by directly using flow cytometric data. Our FCM-Former achieves an accuracy of 96.5% assigning lineage to each sample among 960 cases of either acute B-cell, T-cell lymphoblastic, and acute myeloid leukemia (B-ALL, T-ALL, AML). To the best of our knowledge, the FCM-Former is the first work that automates the immunophenotyping assessment with FCM data in diagnosing pediatric Acute Leukemia.
Read more6/27/2024
0
FlowCyt: A Comparative Study of Deep Learning Approaches for Multi-Class Classification in Flow Cytometry Benchmarking
Lorenzo Bini, Fatemeh Nassajian Mojarrad, Margarita Liarou, Thomas Matthes, St'ephane Marchand-Maillet
This paper presents FlowCyt, the first comprehensive benchmark for multi-class single-cell classification in flow cytometry data. The dataset comprises bone marrow samples from 30 patients, with each cell characterized by twelve markers. Ground truth labels identify five hematological cell types: T lymphocytes, B lymphocytes, Monocytes, Mast cells, and Hematopoietic Stem/Progenitor Cells (HSPCs). Experiments utilize supervised inductive learning and semi-supervised transductive learning on up to 1 million cells per patient. Baseline methods include Gaussian Mixture Models, XGBoost, Random Forests, Deep Neural Networks, and Graph Neural Networks (GNNs). GNNs demonstrate superior performance by exploiting spatial relationships in graph-encoded data. The benchmark allows standardized evaluation of clinically relevant classification tasks, along with exploratory analyses to gain insights into hematological cell phenotypes. This represents the first public flow cytometry benchmark with a richly annotated, heterogeneous dataset. It will empower the development and rigorous assessment of novel methodologies for single-cell analysis.
Read more4/26/2024